Opioid Use Disorder

A surveillance network monitoring maternal, infant and child outcomes tied to medication for opioid use disorder during pregnancy showed different sociodemographics between medication for opioid use disorder and those without, data show.

From 2017 to 2021, people seeking treatment for opioid use disorder increasingly tested positive for fentanyl, methamphetamine and cocaine at presentation, according to findings published in Addiction.

Only one-quarter of residential addiction treatment centers caring for adolescents in the United States offer buprenorphine to patients with opioid use disorder, according to findings published Tuesday in JAMA.

MIAMI BEACH, Fla. — Treatment with subcutaneous buprenorphine on a weekly or monthly basis eased cravings and withdrawals in those with opioid use disorder, per data from the American Society of Clinical Psychopharmacology annual meeting.

There has been a landscape of litigation to hold responsible parties accountable for their part in the opioid crisis.

MIAMI BEACH, Fla. — A literature review of opioid use disorder treatment in correctional facilities found medication-assisted treatments effective but underutilized due to scarce training and resources. “This review points out the situation and deficiencies in medication-assisted treatments for opioid use disorder in correctional facilities throughout the [United States],” Thersilla Oberbarnscheidt, MD, PhD, assistant professor of psychiatry at the University of Pittsburgh, told Healio at the American Society of Clinical Psychopharmacology annual meeting

About 58% of pharmacies reported availability of buprenorphine for opioid use disorder at the time of patients’ requests, according to researchers.

The FDA announced that it has approved Brixadi, an extended-release subcutaneous injection for the treatment of moderate to severe opioid use disorder.

The U.S. Drug Enforcement Agency, or DEA, has announced a temporary extension of prescribing flexibility for controlled substances over telehealth, which was set to expire on May 11.

Postpartum women with opioid use disorder experience a high incidence of postpartum opioid overdose death, other substance-related injuries, accidents and suicide, according to findings published in Obstetrics & Gynecology.